The purpose of this study is to investigate the potential use of Wharton's Jelly Mesenchymal stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2 infection, and showing symptoms of COVID-19.
COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a
high transmission rate and is spreading at very high rates. causing a worldwide pandemic.
Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three
IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each
other.
Patients will be followed up for a period of three weeks to assess the severity of the
condition and measure the viral titers.
Biological: WJ-MSCs
WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.
WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.
Inclusion Criteria:
COVID-19 positive according to diagnosis and clinical management of COVID-19 criteria.
Exclusion Criteria:
- Participants in other clinical trials
- patients with malignant tumors
- pregnant and lactating women
- co-infection with other infectious viruses or bacteria
- History of several allergies
- Patients with history of pulmonary embolism
- any liver or kidney diseases
- HIV positive patients
- Considered by researchers to be not suitable to participate in this clinical trial
- Chronic heart failure with ejection fraction less than 30%.
Stem Cells Arabia
Amman, Jordan
Investigator: Adeeb M Alzoubi, Ph.D.
Contact: +962795337575
adeebalzoubi@stemcellsarabia.net
Investigator:
Adeeb M AlZoubi, Ph.D.
+962795337575
adeebalzoubi@stemcellsarabia.net
Ahmad Y AlGhadi, M.Sc.
+962796624217
ahmed.alghadi@stemcellsarabia.net